UCB

Union Chimique Belge (UCB) is a multinational biopharmaceutical company with its headquarters in Brussels, Belgium. The company, founded in 1928, dedicates itself to the development of pharmaceutical treatments, particularly for central nervous system (CNS) disorders and autoimmune conditions within the field of immunology. Among UCB's notable product offerings are Cimzia (certolizumab pegol), a medication addressing inflammatory diseases such as Crohn's disease and rheumatoid arthritis; Vimpat (lacosamide) and Keppra (levetiracetam), both of which are antiepileptic drugs; Neupro (rotigotine), which is a transdermal patch designed for Parkinson's disease and restless legs syndrome; and Briviact (brivaracetam), another therapy for epilepsy. With a robust international footprint, UCB's products are available globally, enjoying a significant market share across various regions, including Europe, North America, and Asia. The company sees the United States as one of its vital markets, along with a number of European countries where UCB has secured strong positions. (Powered by AI)